Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H553
UPID:
ALG2_HUMAN
Alternative names:
Asparagine-linked glycosylation protein 2 homolog; GDP-Man:Man(1)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase; GDP-Man:Man(1)GlcNAc(2)-PP-dolichol mannosyltransferase; GDP-Man:Man(2)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase
Alternative UPACC:
Q9H553; A2A2Y0; Q8NBX2; Q8NC39
Background:
Alpha-1,3/1,6-mannosyltransferase ALG2, known for its roles in glycoprotein biosynthesis, is pivotal in the process of mannosylation. This enzyme specifically targets Man(2)GlcNAc(2)-dolichol diphosphate and Man(1)GlcNAc(2)-dolichol diphosphate, catalyzing their conversion to Man(3)GlcNAc(2)-dolichol diphosphate. Its alternative names, including Asparagine-linked glycosylation protein 2 homolog, highlight its critical function in protein modification.
Therapeutic significance:
ALG2's involvement in congenital disorders of glycosylation, such as Congenital disorder of glycosylation 1I, and its link to congenital myasthenic syndrome, underscores its therapeutic potential. Targeting ALG2 could lead to novel treatments for these genetic disorders, offering hope for affected individuals.